United States - English - NLM (National Library of Medicine)

bryant ranch prepack - terbinafine hydrochloride (unii: 012c11zu6g) (terbinafine - unii:g7riw8s0xp) - terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (koh) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis. terbinafine tablets are contraindicated in patients with: - chronic or active liver disease [see warnings and precautions (5.1)] - history of allergic reaction to oral terbinafine because of the risk of anaphylaxis [see adverse reactions (6.2)] . risk summary available data from postmarketing cases on the use of terbinafine tablets in pregnant women. are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, terbinafine did not cause malformations or any harm to the fetus when administered to pregnant rabbits and rats during the period of organogenesis at oral doses

United States - English - NLM (National Library of Medicine)

a-s medication solutions - terbinafine hydrochloride (unii: 012c11zu6g) (terbinafine - unii:g7riw8s0xp) - terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (koh) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis. terbinafine tablets are contraindicated in patients with: - chronic or active liver disease [see warnings and precautions (5.1)] - history of allergic reaction to oral terbinafine because of the risk of anaphylaxis [see adverse reactions (6.2)] risk summary available data from postmarketing cases on the use of terbinafine tablets in pregnant women are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, terbinafine did not cause malformations or any harm to the fetus when administered to pregnant rabbits and rats during the period of organogenesis at oral doses up

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - terbinafine hydrochloride, quantity: 281.3 mg (equivalent: terbinafine, qty 250 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; methylcellulose - terbinafine 250 is indicated for: treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infections caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

Canada - English - Health Canada

pro doc limitee - terbinafine (terbinafine hydrochloride) - tablet - 250mg - terbinafine (terbinafine hydrochloride) 250mg - allylamines

Canada - English - Health Canada

qd pharmaceuticals ulc - terbinafine (terbinafine hydrochloride) - tablet - 250mg - terbinafine (terbinafine hydrochloride) 250mg - allylamines

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - terbinafine hydrochloride, quantity: 281.3 mg (equivalent: terbinafine, qty 250 mg) - tablet, uncoated - excipient ingredients: methylcellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica - terry white terbinafine is indicated for: treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infections caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - terbinafine hydrochloride, quantity: 281.3 mg (equivalent: terbinafine, qty 250 mg) - tablet, uncoated - excipient ingredients: methylcellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica - chemmart terbinafine is indicated for: treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infections caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

Canada - English - Health Canada

nu-pharm inc - terbinafine (terbinafine hydrochloride) - tablet - 250mg - terbinafine (terbinafine hydrochloride) 250mg - allylamines

United States - English - NLM (National Library of Medicine)

american health packaging - terbinafine hydrochloride (unii: 012c11zu6g) (terbinafine - unii:g7riw8s0xp) - terbinafine 250 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - terbinafine hydrochloride - oral tablet - 250mg